John Morser Selected Research

Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)

10/2019	TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
10/2013	Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.
2/2013	Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.
4/2012	Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma.
4/2009	Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease.
7/2008	Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
1/2007	A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
4/2006	Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.
12/2003	Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Morser Research Topics

Disease

11	Inflammation (Inflammations) 01/2018 - 12/2003
9	Thrombosis (Thrombus) 04/2017 - 01/2002
4	Hemorrhage 10/2019 - 11/2004
4	Asthma (Bronchial Asthma) 01/2013 - 11/2008
3	Fibrosis (Cirrhosis) 02/2013 - 04/2006
3	Disseminated Intravascular Coagulation 03/2012 - 01/2002
2	Neoplasms (Cancer) 01/2022 - 02/2013
2	Vascular Remodeling 10/2019 - 04/2017
2	Arthritis (Polyarthritis) 01/2018 - 09/2011
2	Glioma (Gliomas) 02/2013 - 11/2011
2	Glioblastoma (Glioblastoma Multiforme) 02/2013 - 11/2011
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 03/2012 - 09/2009
2	Pneumonia (Pneumonitis) 04/2010 - 03/2010
2	Pulmonary Embolism 11/2004 - 02/2002
1	Melanoma (Melanoma, Malignant) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Hemophilia A (Haemophilia) 10/2019
1	Obesity 01/2019
1	Multiple Sclerosis 11/2018
1	Diabetes Mellitus 01/2018
1	Hypoxia (Hypoxemia) 04/2017
1	Pulmonary Hypertension 04/2017
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2016
1	Insulin Resistance 01/2016
1	Acute Lung Injury 10/2013
1	Airway Remodeling 04/2013
1	Respiratory Hypersensitivity 04/2012
1	Atherosclerosis 01/2011
1	Aneurysm (Aneurysms) 08/2010
1	Aortic Aneurysm (Aneurysm, Aortic) 08/2010
1	Hyperglycemia 08/2010
1	Abdominal Aortic Aneurysm 07/2010
1	Pneumococcal Pneumonia 03/2010
1	Rheumatoid Arthritis 10/2009
1	Psoriatic Arthritis 10/2009
1	Osteoarthritis 10/2009
1	Lung Injury 09/2009
1	Obstructive Sleep Apnea 08/2009
1	Thrombophilia 08/2009
1	Sleep Apnea Syndromes (Sleep Apnea) 08/2009
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2009
1	Virus Diseases (Viral Diseases) 06/2009

Drug/Important Bio-Agent (IBA)

9	Thrombin FDA Link 01/2022 - 01/2002
9	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 10/2019 - 12/2003
6	ThrombomodulinIBA 04/2017 - 07/2004
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
4	OsteopontinIBA 01/2022 - 10/2009
4	Bleomycin (Blenoxane)FDA LinkGeneric 02/2013 - 04/2006
3	Plasminogen Activators (Plasminogen Activator)IBA 11/2018 - 11/2004
3	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 09/2009
3	AnticoagulantsIBA 01/2016 - 08/2009
3	Carboxypeptidase BIBA 09/2011 - 10/2009
3	Plasminogen Activator Inhibitor 1IBA 08/2010 - 01/2003
3	Fibrinolysin FDA Link 08/2010 - 07/2008
3	Factor X (Stuart Factor)IBA 09/2009 - 01/2002
3	BatroxobinIBA 07/2008 - 01/2003
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2018 - 11/2004
2	Complement System Proteins (Complement)IBA 10/2013 - 04/2012
2	OvalbuminIBA 04/2012 - 01/2011
2	CytokinesIBA 04/2012 - 10/2009
2	Protein CIBA 08/2009 - 07/2004
2	Fibrinogen (Factor I)FDA Link 07/2008 - 04/2006
2	CollagenIBA 07/2008 - 04/2006
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2008 - 05/2007
2	FibrinIBA 04/2006 - 01/2003
2	Peptides (Polypeptides)IBA 09/2003 - 07/2003
2	EndotoxinsIBA 02/2002 - 01/2002
2	CoagulantsIBA 02/2002 - 01/2002
1	Dabigatran FDA Link 01/2022
1	PlasminogenIBA 10/2019
1	Factor VIII (Coagulation Factor VIII)IBA 10/2019
1	AntibodiesIBA 01/2019
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2018
1	Chymases (Chymase)IBA 01/2018
1	Factor XIa (Coagulation Factor XIa)IBA 01/2018
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2017
1	Protein SIBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 01/2016
1	Blood Glucose (Blood Sugar)IBA 01/2016
1	Complement C5a (Complement 5a)IBA 04/2013
1	Interleukin-5 (Interleukin 5)IBA 04/2012
1	Small Interfering RNA (siRNA)IBA 03/2012
1	Messenger RNA (mRNA)IBA 11/2011
1	Immunoglobulin E (IgE)IBA 01/2011
1	Angiotensin IIIBA 01/2011
1	AllergensIBA 01/2011
1	Ethanol (Ethyl Alcohol)IBA 01/2011
1	ApolipoproteinsIBA 01/2011
1	Pharmaceutical PreparationsIBA 01/2011
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2011
1	N-hydroxy-2-aminopyreneIBA 04/2010
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 03/2010
1	VaccinesIBA 03/2010
1	ImmunosorbentsIBA 10/2009
1	EnzymesIBA 10/2009
1	antithrombin III-protease complexIBA 08/2009
1	Neutralizing AntibodiesIBA 06/2009

Therapy/Procedure

2	Home Nursing (Nursing, Home) 04/2010 - 03/2010
1	Intraperitoneal Injections 01/2011